Romain Boidot, Michael G B Blum, Marie-Pierre Wissler, Céline Gottin, Jiri Ruzicka, Sandy Chevrier, Tiffany M Delhomme, Jérome Audoux, Adrien Jeanniard, Pierre-Alexandre Just, Philipp Harter, Sandro Pignata, Antonio González-Martin, Christian Marth, Johanna Mäenpää, Nicoletta Colombo, Ignace Vergote, Keiichi Fujiwara, Nicolas Duforet-Frebourg, Denis Bertrand, Nicolas Philippe, Isabelle Ray-Coquard, Eric Pujade-Lauraine
BACKGROUND: The PAOLA-1/ENGOT-ov25 trial showed that maintenance olaparib plus bevacizumab increases survival of advanced ovarian cancer patients with homologous recombination deficiency (HRD). However, decentralized solutions to test for HRD in clinical routine are scarce. The goal of this study was to retrospectively validate on tumor samples from the PAOLA-1 trial, the decentralized SeqOne assay, which relies on shallow Whole Genome Sequencing (sWGS) to capture genomic instability and targeted sequencing to determine BRCA status...
March 2, 2024: European Journal of Cancer